期刊
CURRENT CARDIOVASCULAR IMAGING REPORTS
卷 5, 期 1, 页码 19-25出版社
SPRINGER
DOI: 10.1007/s12410-011-9120-6
关键词
Cardiovascular disease; Nanoparticle; Theranostics; Diagnostics; Therapeutics; Cardiac molecular imaging
资金
- International Atherosclerosis Society
- National Heart, Lung, and Blood Institute, National Institutes of Health, as a Program of Excellence in Nanotechnology (PEN) Award [HHSN268201000045C, R01 EB009638, R01 CA155432]
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. New diagnostic and therapeutic strategies are needed to mitigate this public health issue. Advances in nanotechnology have generated innovative strategies for diagnosis and therapy in a variety of diseases, foremost in cancer. Based on these studies, a novel concept referred to as nanomedical theranostics, or the combinatory application of nanoparticulate agents to allow diagnostic therapy, is being explored to enable image-guided, personalized, or targeted treatment. Preclinically, theranostics have been gradually applied to CVD with several interesting and encouraging findings. This article summarizes studies and challenges of nanotheranostic strategies in CVD. It also evaluates nanotheranostic strategies that may potentially be utilized to benefit patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据